ArticleJAMA dermatology2021
Global Harmonization of Morphological Definitions in Hidradenitis Suppurativa for a Proposed Glossary.
Article in JAMA dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa: A Systematic Review.JAMA dermatology · 2022Pooled it
- Modulation of Disease-Associated Pathways in Hidradenitis Suppurativa by the Janus Kinase 1 Inhibitor Povorcitinib: Transcriptomic and Proteomic Analyses of Two Phase 2 Studies.International journal of molecular sciences · 2023Trial
- Evaluation of the Complete Blood Count (CBC) Parameters in Patients With Hidradenitis Suppurativa and Their Correlation With Disease Severity: A Cross-Sectional Study.Health science reports · 2026Article
- Presentations of Cutaneous Disease in Various Skin Pigmentations: Hidradenitis Suppurativa.HCA healthcare journal of medicine · 2026Article
- Hidradenitis suppurativa with and without draining tunnels: A real-world study characterizing differences in treatment and disease burden.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- Hidradenitis Suppurativa Tunnels: Unveiling a Unique Disease Entity.JID innovations : skin science from molecules to population health · 2025Review
- Development and Validation of a Disease-specific Outcomes Tool for the Assessment of Patient Benefits of Treatment for Hidradenitis Suppurativa: the PBI-HS.Acta dermato-venereologica · 2025Article
- The Inflammatory Landscape of a Whole-Tissue Explant Model of Hidradenitis Suppurativa.Experimental dermatology · 2025Article
- Transcriptomic profiling reveals distinct molecular signatures among lesion types in hidradenitis suppurativa.Frontiers in immunology · 2025Article
- Glossary of healthcare pathways: a methodological approach involving a transdisciplinary team in public health.Frontiers in public health · 2024Article
- Biologic drugs in hidradenitis suppurativa: what does the GP have to know? A narrative review.Frontiers in medicine · 2024Review
- Article
- Efficacy of Subantimicrobial, Modified-Release Doxycycline Compared to Regular-Release Doxycycline for the Treatment of Hidradenitis Suppurativa.Skin appendage disorders · 2022Article
- Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.The British journal of dermatology · 2022Article
- Recent advances in hidradenitis suppurativa: Role of race, genetics, and immunology.Frontiers in genetics · 2022Article
- The Genomic Architecture of Hidradenitis Suppurativa-A Systematic Review.Frontiers in genetics · 2022Review
- Importance of Standardized Nomenclature to Advance Hidradenitis Suppurativa Research and Clinical Care.JAMA dermatology · 2021Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
12 authors at 10 institutions in 5 countries.
Funding
Abstract
Importance: Standard morphological terminology and definitions are vital for identification of lesion types in the clinical trial setting and communication about the condition. For hidradenitis suppurativa (HS), morphological definitions have been proposed by different groups, representing various regions of the world, but no international consensus has been reached regarding such definitions. A lack of globally harmonized terminology and definitions may contribute to poor-quality data collection in clinical trials as well as poor communication among clinicians, investigators, and patients. Objective: To establish and validate consensus definitions for typical morphological findings for HS lesions. Methods: This study was conducted from August 2019 to August 2020. A Delphi study technique was used to assess agreement and then resolve disagreement on HS terminology among international experts. After an initial preparation phase, the process consisted of 3 rounds. In each round, participants reviewed preliminary definitions and rated them as "keep, with no changes," "keep, with changes," or "remove." Eight HS primary lesions, including papule, pustule, nodule, plaque, ulcer, abscess, comedo, and tunnel, were selected because they are most frequently used in HS clinician-reported outcome measures. The initial definitions were based on extant literature, and modifications were made between rounds based on qualitative thematic analysis of open-ended responses or discussion. Consensus was defined as greater than 70% to accept a definition. Consensus stability across rounds was defined as less than 15% change in agreement. Reliability was evaluated using the Gwet agreement coefficient. Validation was based on assessment of face validity and stability across rounds. Results: A total of 31 experts participated. All 8 HS primary lesion definitions achieved greater than 70% consensus by Delphi round 3. Stability was achieved for papule, pustule, and abscess. The Gwet agreement coefficient increased from 0.49 (95% CI, 0.26-0.71) in round 1 to 0.78 (95% CI, 0.64-0.92) in round 3. Face validity was supported by expert endorsement to keep terms in survey responses. Previously unmeasured variation among clinicians' definition of tunnels was identified, and consensus was achieved. Conclusions and Relevance: An international group of experts agreed on definitions for morphological features of HS lesions frequently included in HS clinical trials. These international consensus terms and definitions are needed to support consistency of lesion identification and quantification in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.